Foghorn Therapeutics (FHTX) Free Cash Flow Growth (3y) (2022 - 2026)
Foghorn Therapeutics (FHTX) Free Cash Flow Growth (3y) (2022 - 2026) Analysis & Trends
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | FCF Growth (3y) (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 66,861.65 Bn | 66,861.36 Bn | - | -5.05% |
| 2 | Nanobiotix | 1,912.79 Bn | 1,912.72 Bn | - | - |
| 3 | Akari Therapeutics | 1,071.19 Bn | 1,071.19 Bn | - | - |
| 4 | BeOne Medicines | 469.11 Bn | 464.32 Bn | 1.35 Bn | 31.07% |
| 5 | Vertex Pharmaceuticals | 123.03 Bn | 115.78 Bn | 2.59 Bn | 14.71% |
| 6 | Regeneron Pharmaceuticals | 70.13 Bn | 61.37 Bn | 3.31 Bn | -10.65% |
| 7 | Belite Bio | 63.44 Bn | 63.44 Bn | - | - |
| 8 | Argenx Se | 55.97 Bn | 50.78 Bn | 1.41 Bn | - |
| 9 | Alnylam Pharmaceuticals | 37.53 Bn | 34.52 Bn | 959.66 Mn | 31.42% |
| 10 | Foghorn Therapeutics | 342.83 Mn | 253.92 Mn | - | 7.07% |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 7.07% |
| Dec 31, 2025 | 8.30% |
| Sep 30, 2025 | 1.24% |
| Jun 30, 2025 | 10.63% |
| Mar 31, 2025 | -27.82% |
| Dec 31, 2024 | -54.48% |
| Sep 30, 2024 | -0.93% |
| Jun 30, 2024 | -7.57% |
| Mar 31, 2024 | -6.90% |
| Dec 31, 2023 | -87.41% |
| Sep 30, 2023 | -115.95% |
| Jun 30, 2023 | -30.47% |
| Mar 31, 2023 | -37.03% |
| Dec 31, 2022 | -29.45% |